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I have spent over 30 years in industries ranging
from brewing, foods, property and latterly phar-
maceuticals and consumer healthcare.
I am convinced from my own experience that
measuring intangibles for management purposes
does improve performance.
What are these intangible assets? They are the
patents that protect our medicines that take over
ten years of high risk research and development
(R&D) to create; they are the trademarks that pro-
tect our consumer healthcare brands; and in other
industries they are the intellectual property that
have generally taken years of investment and con-
sumer experience to create. The return to compa-
nies and their investors for this significant
development investment is intellectual property
protection that allows for future premium pricing
and higher volume sales. 
GlaxoSmithKline (GSK) has an enterprise value
of some £65bn compared to a net asset value (be-
fore debt) if you look at the most recent consoli-
dated balance sheet of £16bn. The main difference
between the two is the value of the company’s in-
tellectual property comprising its marketed medi-
cines, vaccines and consumer healthcare brands
but also its new product pipeline. Under current
accounting, which I believe to be correct, there is
no capitalisation of internal R&D costs.
Hopefully the preceding paragraph makes clear
that intangibles have significant value for GSK as
they do for many other companies and that this
value is reflected in the premium prices received
for products protected by intangible assets. Given
this value it is important that intangibles are ap-
propriately monitored for internal management
purposes to ensure their value is preserved and en-
hanced.
Certain simple financial measures such as ab-
solute sales and profit values and comparative
growth to previous accounting periods provide
clear measures of performance for both internal
management and for external investors. However,
these generally reflect what has happened rather
than the key drivers of future performance.
My biggest lesson in this respect was when I was
sent as a young accountant to the East Coast of the
US for a short period and worked with a small
restaurant chain which primarily served families.
The business was performing well; sales, profit
and spend per customer were all increasing and
management were pleased with the progress being
made and attributed it to the innovative changes
they had recently made to the menu. However, for-
tunately, there were other measures also used by
management to assess progress in building ‘the
restaurant chain’s value reputation’ as it was this
intangible that was the key to future growth in a
very competitive market. Significantly, one key
measure which was falling was ‘value for money’.
The lesson from this was that sales and profit
would shortly decline if no action was taken as this
sector was highly competitive and very value-for-
money focused. 
Analysis revealed that the new menu with its
greater choice and higher prices may have pleased
most of the restaurant’s customers but did not
please the payer (usually the father in those days)
who found the bill some 20% higher than he ex-
pected. Additionally, although sales were rising the
number of customers began to fall. In conclusion,
the business was forced to change the menu and
delete some of the higher-priced items and fortu-
nately did so before the brand reputation for value
had been inexorably weakened. I left the US with
a clear understanding of the importance of meas-
uring brand health and not being totally focused on
just the key financial measures.
In my present business there are a number of
non-financial measures that provide an assessment
of the intellectual property that drive the majority
of the value of the business. These include, as you
would expect in the pharmaceutical industry, safe-
ty monitoring but also market share and other cus-
tomer market data that monitor the relative
strength of the company’s products. We monitor
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these and react to changes.
Within our R&D organisation, for example, em-
ployees are incentivised based on progress in
meeting objectives to move projects through the
pipeline to approval. This is critical in providing
new medicines for society and for driving future
sales growth.
In conclusion, measuring intangibles which 
represent the most significant part of many com-
panies’ value is important in improving perform-
ance. Linking employee remuneration to these
measures is beneficial where employees have a
direct impact on the measure, but generally not
otherwise. It is important that there is consistency
of measurement over time and that management
focuses on the few key measures that will drive
future value. It is as damaging to dilute manage-
ment by focusing on too many measures as it is to
look at none at all. 
Increasingly in the 21st century, enhancing the
value of intangibles will be key to future wealth
creation and economic prosperity.
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